gsk2251052
Small moleculeexperimental
Clinical trial activity
7 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
5
Phase 2
2
Phase 3
0
Phase 4
0
Earliest trial started Oct 7, 2010 (NCT01262885)
Timeline
Indications
Mechanism of action
- Leucine--tRNA ligaseINHIBITOR
leuS inhibitor
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Also known as
- 3-(aminomethyl)-7-(3-hydroxypropoxy)-1-hydroxy-1,3-dihydro-2,1-benzoxaborole
- gsk052
- gsk2251052
- gsk2251052
- gsk2251052
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01495065 | Phase 1 | Dec 19, 2011 | GlaxoSmithKline |
| NCT01702350 | Phase 1 | Oct 21, 2011 | GlaxoSmithKline |
| NCT01381562 | Phase 2 | Oct 1, 2011 | GlaxoSmithKline |
| NCT01381549 | Phase 2 | Jun 1, 2011 | GlaxoSmithKline |
| NCT01475695 | Phase 1 | Apr 21, 2011 | GlaxoSmithKline |
| NCT01267968 | Phase 1 | Jan 1, 2011 | GlaxoSmithKline |
| NCT01262885 | Phase 1 | Oct 7, 2010 | GlaxoSmithKline |
Showing 7 of 7 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| GlaxoSmithKline | For profit | 7 | 7 | 2 | 2010 |
1 organizations
Page 1 / 1